177 related articles for article (PubMed ID: 37169775)
21. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.
Cheasley D; Fernandez ML; Köbel M; Kim H; Dawson A; Hoenisch J; Bittner M; Chiu DS; Talhouk A; Gilks CB; Jayawardana MW; Pishas KI; Mes-Masson AM; Provencher D; Nigam A; Hacker NF; Gorringe KL; Campbell IG; Carey MS
NPJ Precis Oncol; 2022 Jun; 6(1):47. PubMed ID: 35768582
[TBL] [Abstract][Full Text] [Related]
24. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract][Full Text] [Related]
25. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
McNamara B; Demirkiran C; Hartwich TMP; Bellone S; Manavella D; Mutlu L; Greenman M; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter JA; Santin AD
Gynecol Oncol; 2024 Feb; ():. PubMed ID: 38493021
[TBL] [Abstract][Full Text] [Related]
26. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
[TBL] [Abstract][Full Text] [Related]
27. Low-grade serous ovarian carcinoma: A comprehensive literature review.
Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
[TBL] [Abstract][Full Text] [Related]
28. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.
Ajani MA; Salami A; Awolude OA; Oluwasola AO
Pan Afr Med J; 2017; 27():259. PubMed ID: 29187928
[TBL] [Abstract][Full Text] [Related]
29. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion.
Yemelyanova A; Mao TL; Nakayama N; Shih IeM; Kurman RJ
Am J Surg Pathol; 2008 Dec; 32(12):1800-6. PubMed ID: 18779727
[TBL] [Abstract][Full Text] [Related]
30. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
[TBL] [Abstract][Full Text] [Related]
31. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
Okoye E; Euscher ED; Malpica A
Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
[TBL] [Abstract][Full Text] [Related]
32. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
Hollis RL; Stanley B; Iida Y; Thomson J; Churchman M; Rye T; Mackean M; Nussey F; Gourley C; Herrington CS
Gynecol Oncol; 2019 Nov; 155(2):318-323. PubMed ID: 31495455
[TBL] [Abstract][Full Text] [Related]
33. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract][Full Text] [Related]
34. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
Ahn G; Folkins AK; McKenney JK; Longacre TA
Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
[TBL] [Abstract][Full Text] [Related]
35. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
36. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Grabowski JP; Harter P; Heitz F; Pujade-Lauraine E; Reuss A; Kristensen G; Ray-Coquard I; Heitz J; Traut A; Pfisterer J; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):457-62. PubMed ID: 26807488
[TBL] [Abstract][Full Text] [Related]
37. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
Demir L; Yigit S; Sadullahoglu C; Akyol M; Cokmert S; Kucukzeybek Y; Alacacioglu A; Cakalagaoglu F; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
[TBL] [Abstract][Full Text] [Related]
38. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
39. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.
Gershenson DM; Bodurka DC; Lu KH; Nathan LC; Milojevic L; Wong KK; Malpica A; Sun CC
J Clin Oncol; 2015 Aug; 33(24):2675-82. PubMed ID: 26195696
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
